EnWave starts manufacturing phase of deal with Sutro Biopharma

The company is manufacturing a commercial-scale powderREV machine following the royalty-bearing commercial license that had a machine purchase deal signed in May last year.

Sutro has made a milestone payment to EnWave. The company will make further payments during the manufacture and commissioning of the equipment.

The biopharmaceutical firm uses Xpress CF biochemical protein synthesis technology for discovering and developing novel antibody drug conjugates and multi-specific antibodies for cancer therapeutics.

EnWave will manufacture and install the powderREV machine in 2016 at Sutro’s GMP manufacturing plant in San Carlos, California.

The machine will enable Sutro to dry and store its cell-free extract for pharmaceutical product development and commercialization.

Sutro has been working with EnWave’s powderREV technology since September 2012 for generating dried cell-free extract.

South San Francisco-headquartered Sutro Biopharma is engaged in the development of antibody drug conjugate and multi-specific antibody-based therapeutics for cancer therapy, including Immuno-Oncology therapies.

The company is also collaborating with select pharmaceutical and biotech firms to discover and develop novel therapeutics.